Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
This early phase I trial studies the side effects of ketoconazole and how well it works in
treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the
symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.